| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 259.96 | -3.68 (-1.40%) | 107.31 - 283.99 | 804.9 thousand |
Market data as of 4:00PM 05/21/13. Quotes are delayed by at least 15 min.
| Open | 264.39 |
|---|---|
| Previous Close | 263.64 |
| Day's Range | 255.09 - 266.05 |
| Market Cap | 24.9B |
| Avg Volume (10 Day) | 836.4K |
| Price/Earnings (Trailing 12 Mo.) | 35.1x |
| Earnings Per Share (Trailing 12 Mo.) | 7.52 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Pass |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
PR Newswire - Tuesday 05/21/2013 8:15 AM ET
Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
PR Newswire - Wednesday 05/15/2013 1:00 AM ET
Regeneron Announces Upcoming 2013 Investor Conference Presentations
PR Newswire - Wednesday 05/08/2013 9:30 AM ET
Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs
PR Newswire - Friday 05/03/2013 6:30 AM ET
Regeneron Reports First Quarter 2013 Financial and Operating Results
PR Newswire - Friday 05/03/2013 6:30 AM ET
Regeneron Set to Join the S&P 500; Eagle Materials, CST Brands to Join the S&P MidCap 400; Francesca's, Northern Oil & Gas to Join the S&P SmallCap 600
PR Newswire - Wednesday 04/24/2013 6:18 PM ET
| REGN | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 180.57% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.33 | |
| LT Debt/Equity | 0.33 | |
| Earnings Yield | 2.85% | |
| Price/Sales | 16.28 |
| Company | Last | Change |
|---|---|---|
| Alexion Pharmaceuticals Inc | 102.67 | +2.64% |
| Shire PLC | 96.94 | +1.74% |
| Vertex Pharmaceuticals Inc | 79.47 | +2.70% |
| Illumina Inc | 72.58 | -0.68% |
| BioMarin Pharmaceutical Inc | 65.00 | +4.12% |
Data is delayed by at least 15 min.